THE AUCKLAND BREAST CANCER REGISTER
WHAT IS THE ABCSG?

A multidisciplinary team with a special interest in breast cancer joined together to form the ABCSG in 1976.
The Auckland Breast Cancer Study Group

**Project Staff:** Paula Murray
Mina Christophers
Helen Molony
Troydyn

**Managing Committee:**
Chair: Dr Reena Ramsaroop
Vice-Chair & Scientific Director: Dr V Harvey
Treasurer: Dr Paul Thompson
Executive members: Mr Alex Ng, Dr Erica Whineray Kelly
Personnel Administrator: (ADHB – Currently Sharee Bartlett)

**Membership includes:**
Breast Care Nurses
Radiologists
Surgeons
Pathologists
* Endocrinologists
* Breast Physicians
* Radiation Oncologists
* Medical Oncologists
Recognized that to manage outcomes of breast cancer there is a need for a database

First database 1976 to 1985 – discontinued

1996 – the members agreed that the registry should be re-established

2000 - -
The Auckland Breast Cancer REGISTER

Our Aims:

document:
- the incidence and nature of breast cancer
- treatment methods
- risk factors for recurrence and death

allow the review of:
- current patterns of Care
- defined patients groups, especially Maori, Polynesian and Asian

compare:
- processes of care with guidelines
- actual with predicted outcomes

... and direct further research.
The Auckland Breast Cancer REGISTER

Who is Eligible for Register Monitoring....

Patients with Invasive or (Duct) Insitu Breast Cancer
Cancer first diagnosed on or after June 1, 2000 ;
Living in the 3 Auckland DHBs’ region when first diagnosed ;
Male and Female
The Auckland Breast Cancer REGISTER

What **Consent** is given....

All participants **must** sign a consent form before being included in the study register.
The Auckland Breast Cancer REGISTER

What **Data** is gathered ....

* Clinic Notes
* Screening results
* Pathology results
* Radiotherapy
* Chemotherapy
* Hormone therapy

What **Clinics** participate ....

ALL private and public breast clinics in the greater Auckland region (8)
The Auckland Breast Cancer REGISTER

Current Status of the Register

As at 28/06/10

Total patients on register: 6560
(6717 incidents)

Total ready to be entered: 74

Consent rate: 87%
# Consent Rate by Clinic

<table>
<thead>
<tr>
<th>Clinic Name</th>
<th>Total Pts</th>
<th>Consented</th>
<th>Refused Consent</th>
<th>%Consented</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auckland Breast Centre</td>
<td>171</td>
<td>131</td>
<td>5</td>
<td>77%</td>
</tr>
<tr>
<td>Auckland Hospital</td>
<td>1183</td>
<td>1056</td>
<td>16</td>
<td>89%</td>
</tr>
<tr>
<td>Ascot</td>
<td>257</td>
<td>225</td>
<td>2</td>
<td>88%</td>
</tr>
<tr>
<td>Breast Associates</td>
<td>928</td>
<td>827</td>
<td>14</td>
<td>89%</td>
</tr>
<tr>
<td>Mercy</td>
<td>537</td>
<td>524</td>
<td>7</td>
<td>98%</td>
</tr>
<tr>
<td>Middlemore</td>
<td>1742</td>
<td>1632</td>
<td>6</td>
<td>94%</td>
</tr>
<tr>
<td>North Shore</td>
<td>1905</td>
<td>1613</td>
<td>11</td>
<td>85%</td>
</tr>
<tr>
<td>St Marks</td>
<td>1378</td>
<td>1124</td>
<td>27</td>
<td>82%</td>
</tr>
<tr>
<td>Waitemata Surgeons</td>
<td>152</td>
<td>148</td>
<td>4</td>
<td>97%</td>
</tr>
<tr>
<td>Private/Other/Unknown</td>
<td>167</td>
<td>26</td>
<td>57</td>
<td>16%</td>
</tr>
<tr>
<td></td>
<td><strong>8420</strong></td>
<td><strong>7306</strong></td>
<td><strong>149</strong></td>
<td><strong>87%</strong></td>
</tr>
</tbody>
</table>
INFORMATION

6406 patients were diagnosed with breast cancer in the Auckland region in the time period of 8 years - 1st June 2000 to 31 May 2008

91 % consented to have their data registered – 5698 patients representing 5811 episodes
This data is presented in the poster.
The Auckland Breast Cancer REGISTER

DEMOGRAPHICS

Age Distribution

Age (years)

<30 (n=32)
30-39 (n=383)
40-49 (n=1284)
50-59 (n=1698)
60-69 (n=1251)
70-79 (n=668)
80+ (n=357)
The Auckland Breast Cancer REGISTER

PROGNOSTIC DATA

Her2 Status
(Her2 Tested Only, n=3053)

- Her2 Positive (n=591)
- Her2 Negative (n=2451)
- Equivocal (n=11)

Hormone Status

- Hormone Positive
- Hormone Negative

The diagram shows the distribution of Her2 status and hormone status among the tested cases.
**The Auckland Breast Cancer REGISTER**

**ABSOLUTE 5 YEAR OUTCOME DATA**

**Absolute Five Year Outcome Data** (by patient, 2082 Minimum 5 year follow up)

<table>
<thead>
<tr>
<th>Recurrence Types Including Combinations (n=439)</th>
<th>Totals</th>
<th>% Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loco-Recurrence ALONE</td>
<td>61</td>
<td>2.9%</td>
</tr>
<tr>
<td>2nd Primary ALONE</td>
<td>51</td>
<td>2.4%</td>
</tr>
<tr>
<td>Loco-Recurrence &amp; 2nd Primary</td>
<td>5</td>
<td>0.2%</td>
</tr>
<tr>
<td>Loco-Recurrence &amp; Metastases</td>
<td>65</td>
<td>3.1%</td>
</tr>
<tr>
<td>Metastases &amp; 2nd Primary</td>
<td>9</td>
<td>0.4%</td>
</tr>
<tr>
<td>Metastases ALONE</td>
<td>244</td>
<td>11.7%</td>
</tr>
<tr>
<td>All 3</td>
<td>4</td>
<td>0.2%</td>
</tr>
<tr>
<td>Total</td>
<td>439</td>
<td>21.1%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Recurrence Type at First Detection</th>
<th>On Presentation</th>
<th>&lt;6 months</th>
<th>6-12 months</th>
<th>12-24 months</th>
<th>24+ months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loco-Recurrence</td>
<td>0</td>
<td>10</td>
<td>18</td>
<td>31</td>
<td>58</td>
</tr>
<tr>
<td>Metastatic</td>
<td>26</td>
<td>38</td>
<td>17</td>
<td>70</td>
<td>111</td>
</tr>
<tr>
<td>2nd Primary</td>
<td>0</td>
<td>1</td>
<td>4</td>
<td>10</td>
<td>45</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mortality by PrimaryCause (n=398)</th>
<th>Age</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cause</td>
<td>&lt;30</td>
<td>30 to 39</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>5</td>
<td>21</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Survival</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Survival Rate</td>
<td>1684</td>
<td>81%</td>
</tr>
<tr>
<td>Disease Free Survival</td>
<td>1507</td>
<td>72%</td>
</tr>
</tbody>
</table>
## The Auckland Breast Cancer REGISTER

<table>
<thead>
<tr>
<th></th>
<th>Value 1</th>
<th>Value 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall 5 Year Survival Rate</td>
<td>1688</td>
<td>81%</td>
</tr>
<tr>
<td>- Breast Cancer Specific</td>
<td></td>
<td>86%</td>
</tr>
<tr>
<td>Disease-Free 5 Year Survival</td>
<td>1509</td>
<td>72%</td>
</tr>
<tr>
<td>- Breast Cancer Specific</td>
<td></td>
<td>77%</td>
</tr>
</tbody>
</table>
MALE BREAST DATA
FUTURE OBJECTIVES

• To produce the biannual reports
• To encourage use of the data (within the regulations of the constitution) for presentations and publications - with acknowledgements to the database.
• To disseminate this information to clinicians to enable them to manage their patients more efficiently.
• Publications
• Conference
FUTURE

3 more registries – Waikato, Christchurch, Wellington

??National database
The Auckland Breast Cancer Study Group gratefully acknowledges the past and present support of:

- The Maurice and Phyllis Paykel Trust
  - Avon Cosmetics
  - Scottwood Group
- Mary Kay Cosmetics
  - Webber Trust
- AstraZeneca
The New Zealand Breast Cancer Foundation